-
2025-521036-11-00
5
2026-03-23
Immune system disseases
-
2025-521035-37-00
5
2026-03-02
Immune system diseases
-
2025-522514-23-00
5
2026-02-12
Urinary Incontinence
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-520771-59-00
4
2026-02-03
Atopic Dermatitis
-
2025-522370-36-00
4
2026-02-02
Moderate to Severe Atopic Dermatitis
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2025-523612-37-00
3
2026-01-23
Parkinson's Disease and Apathy
-
2024-519554-37-00
5
2026-01-16
Phenylketonuria
-
2024-514435-20-00
5
2025-12-23
Phenylketonuria
-
2024-518465-10-00
4
2025-12-12
Multiple Autoimmune Glomerular Diseases
-
2024-519712-13-00
5
2025-12-08
Hypertriglyceridemia (HTG)
-
2025-522452-16-00
4
2025-12-05
Endometriosis related pain
-
2025-521382-27-00
10
2025-12-04
Moderately to Severely Active Crohn's Disease
-
2025-521381-10-00
5
2025-12-03
Moderately to Severely Active Ulcerative Colitis
-
2025-521242-26-00
4
2025-11-27
Moderately to Severely Active Ulcerative Colitis
-
2025-521892-30-00
5
2025-11-24
Primary isolated CABG patients with stable coronary artery disease (ch
-
2025-521920-31-00
4
2025-11-21
Graves’ Disease
-
2023-508935-30-00
5
2025-11-20
Lower extremity artery disease
-
2024-517553-26-00
5
2025-11-12
Advanced ALK-positive non-small cell lung cancer (NSCLC)
-
2024-519345-30-00
5
2025-11-12
IgA nephropathy
-
2024-518156-24-00
5
2025-11-10
Atopic Dermatitis
-
2025-520690-39-00
4
2025-11-04
Moderately to Severely Active Ulcerative Colitis (UC)
-
2024-517184-23-00
4
2025-10-16
platinum-resistant advanced high-grade epithelial ovarian, primary per